Schedule 13G ownership disclosure

Relmada Therapeutics Inc

Common Stock ($.001 par value) · CUSIP: 75955J402

Event date: 2025-06-30

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Squadron Master Fund LP

    Shares: 2,914,495.00 · Class: 8.8%

  • Squadron Capital Management LLC

    Shares: 3,298,500.00 · Class: 9.9%

  • William Blank

    Shares: 3,298,500.00 · Class: 9.9%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0002050709-25-000005
Form type
SCHEDULE 13G/A
Filer
RELMADA THERAPEUTICS, INC.
CIK
CIK 1553643
Filed
Aug 14, 2025
Reporting period
Jun 30, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub